Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Octreotide acetate
Drug ID BADD_D01595
Description Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528]
Indications and Usage For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Marketing Status Prescription; Discontinued
ATC Code H01CB02
DrugBank ID DB00104
KEGG ID D02250
MeSH ID D015282
PubChem ID 6917964
TTD Drug ID D02XIY
NDC Product Code 59651-004; 0078-0180; 76177-119; 67457-245; 65015-840; 55463-0035; 25021-451; 0703-3333; 0703-3301; 63415-0065; 67457-246; 0078-0182; 0703-3311; 0641-6174; 0078-0818; 66558-0192; 63323-378; 0641-6177; 63323-376; 0703-3321; 63323-379; 63629-8831; 0641-6176; 0641-6175; 66558-0180; 65129-1049; 25021-452; 0078-0811; 63557-0019; 25021-454; 63323-377; 25021-455; 67457-239; 0703-3343; 0641-6178; 25021-453; 52416-123; 0078-0825; 32861-0005; 0078-0181
Synonyms Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin
Chemical Information
Molecular Formula C51H70N10O12S2
CAS Registry Number 79517-01-4
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4= CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abdominal rigidity07.01.05.011--Not Available
Abdominal tenderness07.01.05.004--Not Available
Abnormal faeces07.01.03.001--Not Available
Acne23.02.01.001--Not Available
Acne cystic23.02.01.005--Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Amenorrhoea21.01.02.001; 05.05.01.002--
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anorectal disorder07.03.01.001--Not Available
Anxiety19.06.02.002--
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Back pain15.03.04.005--
Basal cell carcinoma16.03.02.001; 23.08.02.001--Not Available
Bladder pain20.02.02.001--Not Available
Blood creatine phosphokinase increased13.04.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages